EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke

Yun Chen iD, Lingling Jiang iD, Ying Gao, Weiqi Chen iD, Hongyi Yan iD, Tingting Wang iD, Yingying Yang iD, Dongxiao Yao iD, Dandan Liu iD, Yuesong Pan iD, Yilong Wang iD

Stroke · 2025-11 · 56 (11) · 3108-3117

DOI: 10.1161/strokeaha.125.052167 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2025-11. Verfasst von Yun Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (Y.C., L.J., Y.G., W.C., H.Y., T.W., Y.Y., D.Y., D.L., Y.P., Y.W…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Clopidogrel, Platelet Aggregation Inhibitors, Ischemic Stroke. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The aim of this study was to investigate the clinical outcomes of clopidogrel-aspirin therapy initiated between 24 and 72 hours from the symptom onset among patients with minor stroke or transient ischemic attack stratified by CYP2C19 loss-of-function allele status. METHODS: This was a prespecified secondary analysis of the INSPIRES trial (Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis), which was a randomized clinical trial conducted across 222 centers in China from September 2018 to October 2022. Two loss-of-function alleles ( CYP2C19*2 , CYP2C19*3 ) and 1 gain-of-function allele ( CYP2C19*17 ) were genotyped in the INSPIRES study. Patients with CYP2C19 loss-of-function allele carriers were patients with either CYP2C19*2 or CYP2C19*3 . All participants were randomized to receive clopidogrel-aspirin or aspirin treatment, and those started treatment between 24 and 72 hours from the symptom onset were included in this study. The primary efficacy outcome was new stroke within 90 days. The primary safety outcome was moderate-to-severe bleeding. Cox proportional hazards models were performed to estimate the interaction between treatment assignment and CYP2C19 loss-of-function allele status for the primary outcomes. RESULTS: Among 5003 patients, 2911 (58.2%) patients were loss-of-function carriers, and 2092 (41.8%) patients were noncarriers. Relative to aspirin alone, clopidogrel-aspirin reduced the rate of new stroke in the noncarriers (hazard ratio, 0.67 [95% CI, 0.49–0.91]; P =0.01) but not in the carriers (hazard ratio, 0.96 [95% CI, 0.73–1.25], P =0.74; P =0.09 for interaction). For the safety outcome, moderate-to-severe bleeding did not vary significantly between the carriers (hazard ratio, 1.83 [95% CI, 0.68–4.95]; P =0.23) and noncarriers (hazard ratio, 2.07 [95% CI, 0.62–6.88], P =0.23; P =0.88 for interaction). CONCLUSIONS: Clopidogrel-aspirin treatment presented a priority to aspirin in reducing the risk of new stroke in CYP2C1 9 loss-of-function noncarriers when administered between 24 and 72 hours after stroke onset. These findings supported the necessity of CYP2C19 genotyping in the choice of antiplatelet therapy with an extended treatment window to 72 hours. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03635749.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19ClopidogrelPlatelet Aggregation InhibitorsIschemic StrokeHumansMaleFemaleMiddle AgedAgedAspirinGenotypeTreatment OutcomeTime Factors

Stichwörter der Autor:innen

allelesclopidogrelhumansstroketransient ischemic stroke

Substanzen

Cytochrome P-450 CYP2C19ClopidogrelPlatelet Aggregation InhibitorsCYP2C19 protein, humanAspirin

Autor:innen und Institutionen

  • Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (Y.C., L.J., Y.G., W.C., H.Y., T.W., Y.Y., D.Y., D.L., Y.P., Y.W.).
  • China National Clinical Research Centre for Neurological Diseases, Beijing, China (L.J., Y.G., W.C., H.Y., T.W., Y.Y., Y.P., Y.W.).
  • Chinese Institute for Brain Research, Beijing, China (Y.W.).
  • National Centre for Neurological Diseases, Beijing, China (Y.W.).
  • Advanced Innovation Centre for Human Brain Protection, Capital Medical University, Beijing, China (Y.W.).
  • Beijing Laboratory of Oral Health, Capital Medical University, China (Y.W.).

ORCID-Profile: Yun Chen, Lingling Jiang, Weiqi Chen, Hongyi Yan, Tingting Wang, Yingying Yang, Dongxiao Yao, Dandan Liu, Yuesong Pan, Yilong Wang

Zitieren

APA

Chen, Y., Jiang, L., Gao, Y., Chen, W., Yan, H., Wang, T., Yang, Y., Yao, D., Liu, D., Pan, Y., & Wang, Y. (2025). CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke. Stroke, 56(11), 3108-3117. https://doi.org/10.1161/strokeaha.125.052167

Vancouver

Chen Y, Jiang L, Gao Y, Chen W, Yan H, Wang T, et al. CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke. Stroke. 2025;56(11):3108-3117. doi:10.1161/strokeaha.125.052167

BibTeX
@article{Chen2025,
  author = {Chen, Yun and Jiang, Lingling and Gao, Ying and Chen, Weiqi and Yan, Hongyi and Wang, Tingting and Yang, Yingying and Yao, Dongxiao and Liu, Dandan and Pan, Yuesong and Wang, Yilong},
  title = {CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke},
  journal = {Stroke},
  year = {2025},
  volume = {56},
  number = {11},
  pages = {3108--3117},
  doi = {10.1161/strokeaha.125.052167}
}
Kostenlos starten →